Cell Treatment and Lysis in 96-Well Filter-Bottom Plates for Screening Bcr-Abl Activity and Inhibition in Whole-Cell Extracts

Journal of Biomolecular Screening

Volumn 15, Issue 4, 2010, Pages 434-440

  Mand, Michael R ^a,b   Wu, Ding ^b   Veach, Darren R ^c   Kron, Stephen J ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bcr abl; Cell lysis; Imatinib; Lead identification; Secondary assay

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BCR ABL PROTEIN; DASATINIB; DV 1 10; DV 2 271; DV 2 273; DV 2 281; DV 2 289; DV 2 37; DV 2 43; DV 2 47; DV 2 89; DV 3 081; DV 3 096; DV 5 31; IMATINIB; PD 173952; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; CULTURE MEDIUM; CYTOLYSIS; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SUSPENSION CELL CULTURE;

CELL EXTRACTS; CELL FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FUSION PROTEINS, BCR-ABL; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES;

EID: 77952367552     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110363307     Document Type: Article

References (28)

1. Bleicher KH, Bohm HJ, Muller K, Alanine AI: Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003;2: 369-378. (Pubitemid 37361707)
2. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, et al: 2-Aminothiazole as a novel kinase inhibitor template: structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6- [4-(2-hydroxyethyl)-l-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006;49:6819-6832. (Pubitemid 44749749)
3. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB: Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorgan Med Chem Lett 1997;7:187-192. (Pubitemid 27046418)
4. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 1973;243:290-293.
5. Kantaijian HM, Talpaz M, Giles F, O'Brien S, Cortes J: New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-923. (Pubitemid 351639967)
6. Gone ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
7. Nardi V, Azam M, Daley GQ: Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35-43. (Pubitemid 38021719)
8. Wu D, Mand MR, Veach DR, Parker LL, Clarkson B, Kron SJ: A solidphase Bcr-Abl kinase assay in 96-well hydrogel plates. Anal Biochem 2008;375:18-26.
9. Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, et al: 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones: structureactivity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998;41:3276-3292. (Pubitemid 28376533)
10. Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, et al: Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J Med Chem 1998;41:4365-4377. (Pubitemid 28498760)
11. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-334.
12. Songyang Z, Carraway KL III, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, et al: Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 1995;373:536-539.
13. Pisabarro MT, Serrano L: Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain. Biochemistry 1996;35:10634-10640. (Pubitemid 26279642)
14. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
15. Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-423. (Pubitemid 37013211)
16. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566. (Pubitemid 26151518)
17. Wang JY: Eph tumour suppression: the dark side of Gleevec. Nat Cell Biol 2006;8:785-786.
18. Ghosh G, Lee AG, Palecek SP: Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates. Anal Biochem 2009;393:201-214.
19. Warmuth M, Kim S, Gu XJ, Xia G, Adrian F: Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007;19:55-60. (Pubitemid 44885601)
20. Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohaček RS, Wang Y, et al: Activity of dual SRC-ABL inhibitors highlights the role of BCR/ ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006;103:9244-9249. (Pubitemid 43902563)
21. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-4243. (Pubitemid 34827278)
22. Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN, et al: Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002;16:1589-1595.
23. Dorsey JF, Jove R, Kraker AJ, Wu J: The pyrido[2,3-d]pyrimidine derivative PD 180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000;60:3127-3131. (Pubitemid 30407904)
24. von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, et al: Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003;63:6395-6404. (Pubitemid 37255189)
25. Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bommann WG, et al: Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 2004;18:1352-1356. (Pubitemid 39136744)
26. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, et al: Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002;62:4244-4255. (Pubitemid 34827279)
27. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505. (Pubitemid 40740783)
28. Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, et al: Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 2007;50:5853-5857. (Pubitemid 350106039)